Brown & Brown
BRO
$0.00
+3.92%
Brown & Brown, Inc. is a diversified insurance intermediary operating in the Financial Services sector, specifically within the Insurance Brokers industry, providing retail and wholesale brokerage, insurance programs, and related services. The company is a significant player in the fragmented insurance distribution market, distinguishing itself through a decentralized, entrepreneurial operating model and a consistent track record of growth via strategic acquisitions. The current investor narrative centers on its ability to navigate a challenging insurance market cycle, with recent attention focused on its strategic acquisition activity, such as the purchase of The Protectorate Group, to expand its dealer services division, and the debate around its stock's significant underperformance relative to the broader market over the past year.…
BRO
Brown & Brown
$0.00
Related headlines
BRO 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Brown & Brown's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
7 analysts
Implied Upside
—
vs. current price
Analyst Count
7
covering this stock
Price Range
$0 - $0
Analyst target range
Analyst coverage for BRO is limited, with only 7 analysts providing estimates, indicating this is a mid-cap stock with less institutional scrutiny than larger peers. The consensus sentiment appears neutral to cautious, as evidenced by recent institutional rating actions including a downgrade from Citigroup (Buy to Neutral) and several reiterations of 'Equal Weight', 'Market Perform', or 'Hold' ratings from firms like Barclays, Wells Fargo, and Morgan Stanley in early 2026, though Mizuho provided a positive note upgrading to 'Outperform' in February. The estimated EPS range for the forward period is tight, from a low of $5.08 to a high of $5.37, with an average of $5.26, and the revenue estimate average is $7.90 billion; the narrow target spread on EPS suggests analysts have relatively high conviction in near-term earnings projections, but the limited number of covering analysts and mixed rating actions point to underlying uncertainty regarding the stock's near-term catalyst path and its ability to reverse the significant price decline.
Bulls vs Bears: BRO Investment Factors
The evidence is currently mixed but leans bearish due to the overwhelming technical damage and negative market sentiment, despite strong underlying fundamentals. The bull case is anchored in robust revenue growth (53% YoY), a healthy balance sheet, and a forward P/E that prices in a significant earnings recovery. The bear case is dominated by the stock's catastrophic -41% annual decline, elevated trailing valuation relative to peers, and cautious analyst stance. The single most important tension in the investment debate is whether the company's strong fundamental growth and cash generation can overcome the severe negative price momentum and investor skepticism that has driven the stock to near 52-week lows. The resolution of this tension—specifically, whether upcoming earnings can demonstrate stable margin expansion and validate the forward P/E—will determine the stock's direction.
Bullish
- Strong Revenue Growth and Profitability: Q4 2025 revenue grew 53.26% YoY to $1.669 billion, driven by the larger Specialty Distribution segment. The company maintains robust profitability with a net margin of 17.65% and a gross margin of 87.68%, indicating a highly efficient brokerage model.
- Compelling Forward Valuation: The forward P/E of 13.18x is nearly half the trailing P/E of 23.44x, signaling the market expects significant earnings growth. This forward multiple is more in line with industry averages, suggesting the stock may be undervalued if earnings targets are met.
- Solid Financial Foundation: The balance sheet is healthy with a manageable debt-to-equity ratio of 0.63 and strong free cash flow generation of $1.43 billion TTM. This provides ample capital to fund the acquisitive growth strategy and weather market cycles without financial distress.
- Recent Positive Momentum and Deep Value: The stock is up 13.04% over the past month, showing a potential reversal from its severe downtrend. Trading at $64.22, it is near the lower end of its 52-week range ($53.81-$111.09), representing a potential deep-value entry point after a -41.23% annual decline.
Bearish
- Severe Technical Downtrend and Underperformance: The stock is down 41.23% over the past year and 20.50% over the past six months, with a maximum drawdown of -52.05%. This extreme negative momentum and underperformance versus the SPY's +19.14% gain indicate deep-seated investor skepticism and a broken price trend.
- Elevated Trailing Valuation vs. Peers: A trailing P/E of 23.44x is elevated for an insurance broker, which typically trades in the mid-to-high teens. This premium valuation, despite the price collapse, suggests the market may still be pricing in unrealistic growth expectations or that further multiple compression is possible.
- Analyst Caution and Limited Coverage: Analyst sentiment is neutral-to-cautious, with recent actions including a downgrade from Citigroup (Buy to Neutral) and several 'Hold' or 'Market Perform' reiterations. Limited coverage from only 7 analysts reduces visibility and institutional support for a near-term rally.
- Earnings and Margin Volatility: Quarterly net income has shown volatility ($331M, $231M, $227M, $264M across 2025), indicating a lack of consistent earnings expansion. While revenue growth is strong, this earnings volatility raises questions about the sustainability and quality of profit growth.
BRO Technical Analysis
The prevailing price trend for BRO is a pronounced downtrend, with the stock down 41.23% over the past year and trading at a current price of $64.22, which is approximately 58% of its 52-week range ($53.81 low to $111.09 high). This positioning near the lower end of its annual range suggests the stock is in a deep correction, presenting a potential value opportunity but also indicating significant negative momentum that must be respected. Recent short-term momentum shows a tentative recovery, with the stock up 13.04% over the past month and 1.25% over the past three months, a notable divergence from the severe longer-term downtrend; however, this nascent uptick must be viewed in the context of a 20.50% decline over the last six months and a maximum drawdown of -52.05%, signaling extreme volatility and investor skepticism. Key technical levels are clearly defined by the 52-week low of $53.81, which now serves as critical support, and the 52-week high of $111.09, representing formidable overhead resistance; a sustained breakdown below $53.81 could trigger another leg down, while a breakout above resistance seems distant given the current price. The stock's beta of 0.624 indicates it is approximately 37% less volatile than the broader market (SPY), which is unusual given its recent price swings but suggests it may offer some defensive characteristics in a turbulent market.
Beta
0.60
0.60x market volatility
Max Drawdown
-52.0%
Largest decline past year
52-Week Range
$54-$109
Price range past year
Annual Return
-35.1%
Cumulative gain past year
| Period | BRO Return | S&P 500 |
|---|---|---|
| 1m | +23.7% | -1.3% |
| 3m | +6.1% | +13.6% |
| 6m | -9.8% | +9.0% |
| 1y | -35.1% | +19.1% |
| ytd | -9.8% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BRO Fundamental Analysis
Revenue growth remains robust, with the most recent quarterly revenue (Q4 2025) at $1.669 billion, representing a significant 53.26% year-over-year increase; this growth is primarily driven by the larger Specialty Distribution segment, which contributed $1.728 billion in a recent period compared to $919 million from Retail, indicating the wholesale and specialty businesses are the primary growth engines. The company is highly profitable, reporting net income of $264 million for Q4 2025 with a strong net margin of 17.65% and an impressive gross margin of 87.68%; however, a sequential review of quarterly net income shows some volatility ($331M in Q1 2025, $231M in Q2, $227M in Q3, $264M in Q4), suggesting margin stability rather than consistent expansion, which is typical for a brokerage model reliant on commission and fee income. Balance sheet and cash flow health is solid, with a manageable debt-to-equity ratio of 0.63, a current ratio of 1.04 indicating adequate short-term liquidity, and the generation of substantial free cash flow, with a trailing twelve-month figure of $1.43 billion; this strong cash generation, coupled with a Return on Equity of 8.40%, supports the company's ability to fund its acquisitive growth strategy and return capital to shareholders without excessive reliance on external financing.
Quarterly Revenue
$1.7B
2025-12
Revenue YoY Growth
+0.53%
YoY Comparison
Gross Margin
+0.83%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BRO Overvalued?
Given the company's consistent profitability with a positive net income of $264 million in the last quarter, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio stands at 23.44x, while the forward PE is significantly lower at 13.18x; this substantial gap implies the market expects a meaningful acceleration in earnings growth, likely factoring in the full-year benefit of recent acquisitions and operational improvements. Compared to industry averages, BRO's trailing PE of 23.44x appears elevated relative to typical insurance broker valuations, which often trade in the mid-to-high teens, suggesting a premium that may be justified by its superior growth profile (53% YoY revenue growth) and its position as a consolidator in the industry. Historically, the stock's own valuation has compressed dramatically from recent highs; the current trailing PE of 23.44x is below the historical high observed in Q3 2025 (34.19x) and is approaching levels seen in early 2024, indicating the market has de-rated the stock significantly, which could signal either a value opportunity if fundamentals remain intact or a pricing-in of deteriorating growth prospects.
PE
23.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 16x~48x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Brown & Brown's primary financial risk is not leverage or liquidity, as its debt-to-equity of 0.63 and current ratio of 1.04 are manageable, but rather earnings volatility. Quarterly net income fluctuated from $331M to $227M in 2025, raising concerns about the predictability of its profit stream despite strong top-line growth. Furthermore, the business model is heavily reliant on the insurance underwriting cycle and commission-based revenue, making margins susceptible to competitive pressure and market hardening/softening. While free cash flow is robust at $1.43B TTM, a significant slowdown in the acquisitive growth engine—a key driver of its historical expansion—could pressure the premium valuation the market has historically awarded it.
Market & Competitive Risks: The most pressing market risk is valuation compression. Despite the steep decline, BRO's trailing P/E of 23.44x remains at a premium to typical insurance broker multiples, leaving it vulnerable to further de-rating if growth decelerates. The stock's beta of 0.624 suggests it should be less volatile than the market, yet its -52% max drawdown contradicts this, indicating company-specific or sector-specific risks are dominating. Competitive risks are inherent in the fragmented brokerage landscape, where scale and client relationships are critical; any failure to integrate acquisitions successfully could impair growth and margins. Recent analyst downgrades to Neutral/Hold reflect this growing caution on near-term catalysts.
Worst-Case Scenario: The worst-case scenario involves a continuation of the current downtrend, catalyzed by a miss on forward EPS estimates (currently $5.26 avg) coupled with a guidance reduction, triggering a wave of analyst downgrades. This could lead to a full valuation re-rating towards a lower industry P/E multiple while growth expectations reset. In this adverse scenario, the stock could retest and break below its 52-week low of $53.81. A decline to that level from the current price of $64.22 represents a potential loss of approximately -16%. A more severe bear case, factoring in a recessionary impact on insurance premiums, could see the stock fall 25-30% from current levels.